WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 401691
Description: PF-4942847 is a novel oral Hsp90 inhibitor, which is a candidate for clinical development in TNBC by collaboratively targeting multiple signaling pathways. In addition, AKT degradation in PBLs may serve as a biomarker in clinical development.
MedKoo Cat#: 401691
Chemical Formula: C20H18Cl2F3N7O2
Exact Mass: 515.08511
Molecular Weight: 516.3
Elemental Analysis: C, 46.53; H, 3.51; Cl, 13.73; F, 11.04; N, 18.99; O, 6.20
Synonym: PF4942847; PF-4942847; PF 4942847; PF04942847
IUPAC/Chemical Name: 2-Amino-4-[2,4-dichloro-6-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-5,7-dihydro-N-(2,2,2-trifluoroethyl)-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
SMILES Code: O=C(N1CC2=NC(N)=NC(C3=C(OCCN4N=CC=C4)C=C(Cl)C=C3Cl)=C2C1)NCC(F)(F)F
1: Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. Clin Cancer Res. 2011 Aug 15;17(16):5432-42. doi: 10.1158/1078-0432.CCR-11-0592. Epub 2011 Jun 29. PubMed PMID: 21715568.